Amgen Inc (AMGN)
300.42
-10.87
(-3.49%)
USD |
NASDAQ |
May 06, 15:42
Amgen Cash from Operations (TTM): 8.096B for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 8.096B |
December 31, 2023 | 8.471B |
September 30, 2023 | 10.58B |
June 30, 2023 | 10.80B |
March 31, 2023 | 8.621B |
December 31, 2022 | 9.721B |
September 30, 2022 | 9.88B |
June 30, 2022 | 9.32B |
March 31, 2022 | 9.321B |
December 31, 2021 | 9.261B |
September 30, 2021 | 8.606B |
June 30, 2021 | 9.556B |
March 31, 2021 | 10.47B |
December 31, 2020 | 10.50B |
September 30, 2020 | 10.86B |
June 30, 2020 | 10.87B |
March 31, 2020 | 9.439B |
December 31, 2019 | 9.15B |
September 30, 2019 | 9.83B |
June 30, 2019 | 9.726B |
March 31, 2019 | 10.41B |
December 31, 2018 | 11.30B |
September 30, 2018 | 11.11B |
June 30, 2018 | 11.30B |
March 31, 2018 | 11.52B |
Date | Value |
---|---|
December 31, 2017 | 11.18B |
September 30, 2017 | 11.26B |
June 30, 2017 | 10.47B |
March 31, 2017 | 10.82B |
December 31, 2016 | 10.35B |
September 30, 2016 | 9.327B |
June 30, 2016 | 9.557B |
March 31, 2016 | 10.16B |
December 31, 2015 | 9.731B |
September 30, 2015 | 10.50B |
June 30, 2015 | 10.35B |
March 31, 2015 | 9.292B |
December 31, 2014 | 8.952B |
September 30, 2014 | 7.945B |
June 30, 2014 | 7.011B |
March 31, 2014 | 6.384B |
December 31, 2013 | 6.291B |
September 30, 2013 | 5.268B |
June 30, 2013 | 5.184B |
March 31, 2013 | 5.959B |
December 31, 2012 | 5.882B |
September 30, 2012 | 6.654B |
June 30, 2012 | 5.90B |
March 31, 2012 | 5.061B |
December 31, 2011 | 5.119B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
8.096B
Minimum
Mar 2024
10.87B
Maximum
Jun 2020
9.653B
Average
9.638B
Median
Cash from Operations (TTM) Benchmarks
Gilead Sciences Inc | 8.481B |
Johnson & Johnson | 23.19B |
Eli Lilly and Co | 3.676B |
Merck & Co Inc | 13.01B |
Vertex Pharmaceuticals Inc | 3.537B |